Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.70 |
| ▸ | ALPI | P09923 | 1/20 | 0.70 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | XIAP | P98170 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | FYN | P06241 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | TPH1 | P17752 | 1/20 | 0.59 |
| ▸ | GRB2 | P62993 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43851 | 1.00 | SLC7A5 (0.71) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL43852 | 1.00 | SLC7A5 (0.71) | SLC7A5PTGS1ALPIPKMXIAP | |
| Water SCHEMBL2776212 | 0.98 | SLC7A5 (0.69) | SLC7A5PTGS1ALPIPKMXIAP | |
| Hydrochloric Acid SCHEMBL28269648 | 0.98 | SLC7A5 (0.69) | SLC7A5PTGS1ALPIPKMXIAP | |
| Water SCHEMBL2778595 | 0.98 | SLC7A5 (0.69) | SLC7A5PTGS1ALPIPKMXIAP | |
| Hydrochloric Acid SCHEMBL3873365 | 0.98 | SLC7A5 (0.69) | SLC7A5PTGS1ALPIPKMXIAP | |
| Water SCHEMBL2310847 | 0.98 | SLC7A5 (0.69) | SLC7A5PTGS1ALPIPKMXIAP | |
| Hydrochloric Acid SCHEMBL27245458 | 0.96 | SLC7A5 (0.67) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL31369911 | 0.94 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL16207858 | 0.94 | SLC7A5 (0.81) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 626 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4696699-A1 | ? OPIOID RECEPTOR AGONIST AND USE THEREOF | Chengdu Aoda Biotechnology Co., Ltd. (CN) | 2026-02-18 | — | — | EP | claimed |
| EP-4696700-A1 | LONG-ACTING K-OPIOID RECEPTOR AGONIST | Chengdu Aoda Biotechnology Co., Ltd (CN) | 2026-02-18 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4590345-A2 | HIGH-PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Nuclidium AG (CH) | 2025-07-30 | — | — | EP | claimed |
| CN-119899240-A | Kappa opioid receptor agonist and application thereof | 成都奥达生物科技有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-119838022-A | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-119390765-A | Kappa opioid receptor agonist and application thereof | 成都奥达生物科技有限公司 | 2025-02-07 | — | — | CN | claimed |
| WO-2024240173-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| EP-1131343-A4 | HYDROPHILIC SOMATOSTATIN ANALOGS | ADMINISTRATORS OFTHE TULANE UN (US) | 2005-02-02 | — | — | EP | claimed |
| EP-1483285-A1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | Curacyte AG (DE) | 2004-12-08 | — | — | EP | claimed |
| WO-2003076457-A1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | CURACYTE AG (DE) | 2003-09-18 | — | — | WO | claimed |
| WO-2003006048-A1 | COMBINATION OF CHIPS (CHEMOTAXIS INHIBITING PROTEIN FROM STAPHYLOCOCCUS AUREUS)-BASED COMPOUNDS | JARI PHARMACEUTICALS B.V. (NL) | 2003-01-23 | — | — | WO | claimed |
| US-6465613-B1 | ADMINISTERING A SOMATOSTATIN DERIVATIVE TO A PATIENT FOR SELECTIVELY TARGETING AND ARRESTING THE GROWTH OF AN ANGIOGENIC BLOOD VESSEL OR A CELL | TULANE UNIVERSITY | 2002-10-15 | — | — | US | claimed |
| EP-1208116-A2 | SOMATOSTATIN ANALOGS, RADIOLABELLED DERIVATIVES THEREOF AND THEIR USE | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-05-29 | — | — | EP | claimed |
| US-6358491-B1 | FOR CANCER IMAGING AND THERAPY USING NOVEL SOMATOSTATIN ANALOGS, MEDICAL DIAGNOSIS, RADIOPHARMACEUTICALS | BERLEX LABORATORIES, INC. | 2002-03-19 | — | — | US | claimed |
| EP-1131343-A1 | HYDROPHILIC SOMATOSTATIN ANALOGS | THE ADMINISTRATORS OF THE TULANE UNIVERSITY EDUCATIONAL FUND (US) | 2001-09-12 | — | — | EP | claimed |
| WO-2001044177-A2 | SOMATOSTATIN ANALOGS, RADIOLABELLED DERIVATIVES THEREOF AND THEIR USE | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-06-21 | — | — | WO | claimed |
| WO-2000031122-A1 | HYDROPHILIC SOMATOSTATIN ANALOGS | TULANE UNIVERSITY (US) | 2000-06-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | SLC7A5 241/4885PTGS1 3450/4885ALPI 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.